Seroatlas · Human Serome Atlas

GPR17

Uracil nucleotide/cysteinyl leukotriene receptor

Also known as: GPR17_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q13304
Gene: GPR17
Ensembl: ENSG00000144230
Chromosome: 2
Canonical length: 367 aa
Protein class: G-protein coupled receptors, Predicted membrane proteins
Subcellular location: Vesicles

OverviewNCBI Gene

Predicted to enable G protein-coupled receptor activity. Predicted to be involved in G protein-coupled receptor signaling pathway. Predicted to act upstream of or within negative regulation of inflammatory response to antigenic stimulus. Predicted to be located in membrane. Predicted to be active in plasma membrane. [provided by Alliance of Genome Resources, Jul 2025]

Canonical amino-acid sequenceUniProt

367 residues, UniProt reviewed canonical sequence.

>Q13304|GPR17
     1  MSKRSWWAGS RKPPREMLKL SGSDSSQSMN GLEVAPPGLI TNFSLATAEQ CGQETPLENM
    61  LFASFYLLDF ILALVGNTLA LWLFIRDHKS GTPANVFLMH LAVADLSCVL VLPTRLVYHF
   121  SGNHWPFGEI ACRLTGFLFY LNMYASIYFL TCISADRFLA IVHPVKSLKL RRPLYAHLAC
   181  AFLWVVVAVA MAPLLVSPQT VQTNHTVVCL QLYREKASHH ALVSLAVAFT FPFITTVTCY
   241  LLIIRSLRQG LRVEKRLKTK AVRMIAIVLA IFLVCFVPYH VNRSVYVLHY RSHGASCATQ
   301  RILALANRIT SCLTSLNGAL DPIMYFFVAE KFRHALCNLL CGKRLKGPPP SFEGKTNESS
   361  LSAKSEL

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against GPR17 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Cell surface
Secreted: No
Transmembrane segments: 7
Mean surface accessibility (rSASA): 0.35
Highest tissue expression: 35 nTPM

Expression across tissuesHPA

Tissue

cerebral cortex: 35 nTPM
skeletal muscle: 7.9 nTPM
colon: 7.3 nTPM
heart muscle: 7 nTPM
spleen: 7 nTPM
endometrium: 5.1 nTPM

Single-cell type

oligodendrocytes: 264 nCPM
oligodendrocyte progenitor cells: 131 nCPM
cardiomyocytes: 77 nCPM
vascular endothelial cells: 7.6 nCPM
schwann cells: 3.8 nCPM
epicardial cells: 2.3 nCPM

Immune cell

naive B-cell: 1.9 nTPM
myeloid DC: 0.1 nTPM
basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM

Brain region

amygdala: 48 nTPM
white matter: 44 nTPM
medulla oblongata: 43 nTPM
pons: 41 nTPM
cerebral cortex: 38 nTPM
midbrain: 38 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 1.46
gnomAD pLI: 0
gnomAD missense Z: 0.08
DepMap mean gene effect: -0.11
DepMap dependency class: selective

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

plasma membrane

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads GPR17 as an antibody target. Whether an autoantibody or antibody against GPR17 could matter depends on whether native GPR17 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

GPR17 is annotated at the cell surface, where native GPR17 is exposed to circulating antibodies and is a prime autoantibody target that could block, deplete, or overstimulate it.

Annotation status

The present source text does not explicitly label GPR17 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...